Trial Outcomes & Findings for Memantine for Recurrent Glioblastoma (NCT NCT01260467)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

4 participants

Primary outcome timeframe

30 months

Results posted on

2015-12-10

Participant Flow

Participant milestones

Participant milestones
Measure	Single Agent Memantine Group memantine:10 milligrams orally twice a day
Overall Study STARTED	4
Overall Study COMPLETED	2
Overall Study NOT COMPLETED	2

Reasons for withdrawal

Reasons for withdrawal
Measure	Single Agent Memantine Group memantine:10 milligrams orally twice a day
Overall Study Withdrawal by Subject	2

Baseline Characteristics

Memantine for Recurrent Glioblastoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Single Agent Memantine Group n=4 Participants memantine:10 milligrams orally twice a day
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	3 Participants n=5 Participants
Age, Categorical >=65 years	1 Participants n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	3 Participants n=5 Participants
Region of Enrollment United States	4 participants n=5 Participants

PRIMARY outcome

Timeframe: 30 months

Population: not evaluated due to poor patient accrual

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 24 months

Population: not evaluated due to poor patient accrual

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 months

This study will look at the number of participants who develop adverse events or side effects thought to be related to the memantine.

Outcome measures

Outcome measures
Measure	Single Agent Memantine Group n=4 Participants memantine:10 milligrams orally twice a day
Number of Participants With Adverse Events	0 participants

Adverse Events

Single Agent Memantine Group

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Serventi Research Associate

University of Rochester Medical Center

Phone: 585-276-3971

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place